Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 86 entries
Sorted by: Best Match Show Resources per page
Promoting industrial diversification in resource intensive economies: the experiences of Sub-Saharan Africa and Central Asia regions

STEM and diversification

Alcorta L, Kaplinsky R.
GSID: gzMDxesoeS0J
R Kaplinsky, M Farooki, L Alcorta, N Rodousakis - 2012 - oro.open.ac.uk

In the context of the post-2003 commodity price boom, this UNIDO Report focuses on the potential contribution which rising prices can make to the promotion of industrialisation. …

Cite
Kaplinsky, R., Farooki, M., Alcorta, L., & Rodousakis, N. (2012). Promoting industrial diversification in resource intensive economies: the experiences of Sub-Saharan Africa and Central Asia regions. United Nations Industrial Development Organisation.
Kaplinsky, Raphael, et al. Promoting industrial diversification in resource intensive economies: the experiences of Sub-Saharan Africa and Central Asia regions. United Nations Industrial Development Organisation, 2012.
Copy Download .nbib Format: MLA
Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.

SpringerPlus

Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP.
PMID: 26240784
Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015.

BACKGROUND: Breast cancer subtype, determined by expression of estrogen/progesterone receptor (ER/PR) and human epidermal growth factor receptor (HER)-2, is predictive for prognosis. The importance of subtype to locoregional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant...

Cite
Zhang C, Wang S, Israel HP, et al. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015;4:386doi: 10.1186/s40064-015-1116-2.
Zhang, C., Wang, S., Israel, H. P., Yan, S. X., Horowitz, D. P., Crockford, S., Gidea-Addeo, D., Clifford Chao, K. S., Kalinsky, K., & Connolly, E. P. (2015). Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus, 4386. https://doi.org/10.1186/s40064-015-1116-2
Zhang, Chi, et al. "Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy." SpringerPlus vol. 4 (2015): 386. doi: https://doi.org/10.1186/s40064-015-1116-2
Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015. PMID: 26240784; PMCID: PMC4519490.
Copy Download .nbib Format: NLM
¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.

Journal of the Academy of Nutrition and Dietetics

Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, Hershman DL.
PMID: 25911520
J Acad Nutr Diet. 2015 May;115(5):S42-S56.e3. doi: 10.1016/j.jand.2015.02.027.

BACKGROUND: There is a need for culturally relevant nutrition programs targeted to underserved cancer survivors.OBJECTIVE: Our aim was to examine the effect of a culturally based approach to dietary change on increasing fruit/vegetable (F/V) intake and decreasing fat intake...

Cite
Greenlee H, Gaffney AO, Aycinena AC, et al. ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. J Acad Nutr Diet. 2015;115(5):S42-S56.e3doi: 10.1016/j.jand.2015.02.027.
Greenlee, H., Gaffney, A. O., Aycinena, A. C., Koch, P., Contento, I., Karmally, W., Richardson, J. M., Lim, E., Tsai, W. Y., Crew, K., Maurer, M., Kalinsky, K., & Hershman, D. L. (2015). ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. Journal of the Academy of Nutrition and Dietetics, 115(5), S42-S56.e3. https://doi.org/10.1016/j.jand.2015.02.027
Greenlee, Heather, et al. "¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors." Journal of the Academy of Nutrition and Dietetics vol. 115,5 (2015): S42-S56.e3. doi: https://doi.org/10.1016/j.jand.2015.02.027
Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, Hershman DL. ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. J Acad Nutr Diet. 2015 May;115(5):S42-S56.e3. doi: 10.1016/j.jand.2015.02.027. PMID: 25911520; PMCID: PMC5369235.
Copy Download .nbib Format: NLM
Mathematics vs. Numerical Analysis.

Science (New York, N.Y.)

Albert AA, Browder FE, Herstein IN, Kaplansky I, Lane SM.
PMID: 17838082
Science. 1965 Jul 16;149(3681):243-4. doi: 10.1126/science.149.3681.243-b.

No abstract available.

Cite
Albert AA, Browder FE, Herstein IN, et al. Mathematics vs. Numerical Analysis. Science. 1965;149(3681):243-4doi: 10.1126/science.149.3681.243-b.
Albert, A. A., Browder, F. E., Herstein, I. N., Kaplansky, I., & Lane, S. M. (1965). Mathematics vs. Numerical Analysis. Science (New York, N.Y.), 149(3681), 243-4. https://doi.org/10.1126/science.149.3681.243-b
Albert, A A, et al. "Mathematics vs. Numerical Analysis." Science (New York, N.Y.) vol. 149,3681 (1965): 243-4. doi: https://doi.org/10.1126/science.149.3681.243-b
Albert AA, Browder FE, Herstein IN, Kaplansky I, Lane SM. Mathematics vs. Numerical Analysis. Science. 1965 Jul 16;149(3681):243-4. doi: 10.1126/science.149.3681.243-b. PMID: 17838082.
Copy Download .nbib Format: NLM
Some Results on Abelian Groups.

Proceedings of the National Academy of Sciences of the United States of America

Kaplansky I.
PMID: 16589142
Proc Natl Acad Sci U S A. 1952 Jun;38(6):538-40. doi: 10.1073/pnas.38.6.538.

No abstract available.

Cite
Kaplansky I. Some Results on Abelian Groups. Proc Natl Acad Sci U S A. 1952;38(6):538-40doi: 10.1073/pnas.38.6.538.
Kaplansky, I. (1952). Some Results on Abelian Groups. Proceedings of the National Academy of Sciences of the United States of America, 38(6), 538-40. https://doi.org/10.1073/pnas.38.6.538
Kaplansky, I. "Some Results on Abelian Groups." Proceedings of the National Academy of Sciences of the United States of America vol. 38,6 (1952): 538-40. doi: https://doi.org/10.1073/pnas.38.6.538
Kaplansky I. Some Results on Abelian Groups. Proc Natl Acad Sci U S A. 1952 Jun;38(6):538-40. doi: 10.1073/pnas.38.6.538. PMID: 16589142; PMCID: PMC1063607.
Copy Download .nbib Format: NLM
Hormones regulating structural changes in the adipocytes of the female earwig Labidura riparia.

Tissue & cell

Sayah F, Karlinsky A, Breuzet M.
PMID: 18621283
Tissue Cell. 1994 Aug;26(4):587-97. doi: 10.1016/0040-8166(94)90011-6.

Changes in periovarian fat body fine structure occur during the reproductive cycle of the female earwig Labidura riparia. During the process of vitellogenesis, high levels of protein synthesis are seen in the adipocytes. Simultaneously, the formerly osmiophilic lipid droplets...

Cite
Sayah F, Karlinsky A, Breuzet M. Hormones regulating structural changes in the adipocytes of the female earwig Labidura riparia. Tissue Cell. 1994;26(4):587-97doi: 10.1016/0040-8166(94)90011-6.
Sayah, F., Karlinsky, A., & Breuzet, M. (1994). Hormones regulating structural changes in the adipocytes of the female earwig Labidura riparia. Tissue & cell, 26(4), 587-97. https://doi.org/10.1016/0040-8166(94)90011-6
Sayah, F, et al. "Hormones regulating structural changes in the adipocytes of the female earwig Labidura riparia." Tissue & cell vol. 26,4 (1994): 587-97. doi: https://doi.org/10.1016/0040-8166(94)90011-6
Sayah F, Karlinsky A, Breuzet M. Hormones regulating structural changes in the adipocytes of the female earwig Labidura riparia. Tissue Cell. 1994 Aug;26(4):587-97. doi: 10.1016/0040-8166(94)90011-6. PMID: 18621283.
Copy Download .nbib Format: NLM
Temperature compensation of auxin dependent developmental patterning.

Plant signaling & behavior

Kaplinsky NJ.
PMID: 20514234
Plant Signal Behav. 2009 Dec;4(12):1157-8. doi: 10.4161/psb.4.12.9949.

The establishment of localized auxin gradients plays a central role in developmental patterning in plants. Auxin levels and responses have been shown to increase with temperature although developmental patterning is not affected. This suggests the existence of a homeostatic...

Cite
Kaplinsky NJ. Temperature compensation of auxin dependent developmental patterning. Plant Signal Behav. 2009;4(12):1157-8doi: 10.4161/psb.4.12.9949.
Kaplinsky, N. J. (2009). Temperature compensation of auxin dependent developmental patterning. Plant signaling & behavior, 4(12), 1157-8. https://doi.org/10.4161/psb.4.12.9949
Kaplinsky, Nicholas J. "Temperature compensation of auxin dependent developmental patterning." Plant signaling & behavior vol. 4,12 (2009): 1157-8. doi: https://doi.org/10.4161/psb.4.12.9949
Kaplinsky NJ. Temperature compensation of auxin dependent developmental patterning. Plant Signal Behav. 2009 Dec;4(12):1157-8. doi: 10.4161/psb.4.12.9949. PMID: 20514234; PMCID: PMC2819444.
Copy Download .nbib Format: NLM
Antiproliferative Properties of Type I and Type II Interferon.

Pharmaceuticals (Basel, Switzerland)

Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC.
PMID: 20664817
Pharmaceuticals (Basel). 2010 Mar 30;3(4):994-1015. doi: 10.3390/ph3040994.

The clinical possibilities of interferon (IFN) became apparent with early studies demonstrating that it was capable of inhibiting tumor cells in culture and in vivo using animal models. IFN gained the distinction of being the first recombinant cytokine to...

Cite
Bekisz J, Baron S, Balinsky C, et al. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010;3(4):994-1015doi: 10.3390/ph3040994.
Bekisz, J., Baron, S., Balinsky, C., Morrow, A., & Zoon, K. C. (2010). Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel, Switzerland), 3(4), 994-1015. https://doi.org/10.3390/ph3040994
Bekisz, Joseph, et al. "Antiproliferative Properties of Type I and Type II Interferon." Pharmaceuticals (Basel, Switzerland) vol. 3,4 (2010): 994-1015. doi: https://doi.org/10.3390/ph3040994
Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010 Mar 30;3(4):994-1015. doi: 10.3390/ph3040994. PMID: 20664817; PMCID: PMC2907165.
Copy Download .nbib Format: NLM
Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy.

Biomedical optics express

Altoe ML, Marone A, Kim HK, Kalinsky K, Hershman DL, Hielscher AH, Ha RS.
PMID: 31453012
Biomed Opt Express. 2019 Aug 01;10(8):4305-4315. doi: 10.1364/BOE.10.004305. eCollection 2019 Aug 01.

The purpose of this study is to evaluate whether a diffuse optical tomography breast imaging system (DOTBIS) can provide a comparable optical-based image index of mammographic breast density, an established biomarker of breast cancer risk. Oxyhemoglobin concentration (ctO

Cite
Altoe ML, Marone A, Kim HK, et al. Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomed Opt Express. 2019;10(8):4305-4315doi: 10.1364/BOE.10.004305.
Altoe, M. L., Marone, A., Kim, H. K., Kalinsky, K., Hershman, D. L., Hielscher, A. H., & Ha, R. S. (2019). Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomedical optics express, 10(8), 4305-4315. https://doi.org/10.1364/BOE.10.004305
Altoe, Mirella L, et al. "Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy." Biomedical optics express vol. 10,8 (2019): 4305-4315. doi: https://doi.org/10.1364/BOE.10.004305
Altoe ML, Marone A, Kim HK, Kalinsky K, Hershman DL, Hielscher AH, Ha RS. Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomed Opt Express. 2019 Aug 01;10(8):4305-4315. doi: 10.1364/BOE.10.004305. eCollection 2019 Aug 01. PMID: 31453012; PMCID: PMC6701514.
Copy Download .nbib Format: NLM
Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

International journal of food science, nutrition and dietetics

Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL.
PMID: 28480224
Int J Food Sci Nutr Diet. 2015;2015:1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23.

Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer prevention. We examined the safety, feasibility, and biomarker effects of high-dose vitamin D among women at high risk for breast cancer. Forty high-risk...

Cite
Crew KD, Xiao T, Thomas PS, et al. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. Int J Food Sci Nutr Diet. 2015;2015:1-16doi: 10.19070/2326-3350-SI01001.
Crew, K. D., Xiao, T., Thomas, P. S., Terry, M. B., Maurer, M., Kalinsky, K., Feldman, S., Brafman, L., Refice, S. R., & Hershman, D. L. (2015). Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. International journal of food science, nutrition and dietetics, 20151-16. https://doi.org/10.19070/2326-3350-SI01001
Crew, K D, et al. "Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer." International journal of food science, nutrition and dietetics vol. 2015 (2015): 1-16. doi: https://doi.org/10.19070/2326-3350-SI01001
Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. Int J Food Sci Nutr Diet. 2015;2015:1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23. PMID: 28480224; PMCID: PMC5415303.
Copy Download .nbib Format: NLM
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Cancer cell

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.
PMID: 34143979
Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17.

The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. Seventy-three participants were randomized to DOP and...

Cite
Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-998.e5doi: 10.1016/j.ccell.2021.05.009.
Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., Beckwith, H., Nanda, R., Albain, K. S., Clark, A. S., Kemmer, K., Kalinsky, K., Isaacs, C., Thomas, A., Shatsky, R., Helsten, T. L., Forero-Torres, A., Liu, M. C., Brown-Swigart, L., Petricoin, E. F., Wulfkuhle, J. D., Asare, S. M., Wilson, A., Singhrao, R., Sit, L., Hirst, G. L., Berry, S., Sanil, A., Asare, A. L., Matthews, J. B., Perlmutter, J., Melisko, M., Rugo, H. S., Schwab, R. B., Symmans, W. F., Yee, D., Van't Veer, L. J., Hylton, N. M., DeMichele, A. M., Berry, D. A., & Esserman, L. J. (2021). Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer cell, 39(7), 989-998.e5. https://doi.org/10.1016/j.ccell.2021.05.009
Pusztai, Lajos, et al. "Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial." Cancer cell vol. 39,7 (2021): 989-998.e5. doi: https://doi.org/10.1016/j.ccell.2021.05.009
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. PMID: 34143979.
Copy Download .nbib Format: NLM
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.

Clinical breast cancer

Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M.
PMID: 33781662
Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.

Triple-negative breast cancer (TNBC), defined as breast cancer lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), accounts for up to 20% of all breast cancer, and it occurs at a higher frequency...

Cite
Mahtani R, Kittaneh M, Kalinsky K, et al. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clin Breast Cancer. 2020;21(5):383-390doi: 10.1016/j.clbc.2020.12.011.
Mahtani, R., Kittaneh, M., Kalinsky, K., Mamounas, E., Badve, S., Vogel, C., Lower, E., Schwartzberg, L., Pegram, M. (2021). Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical breast cancer, 21(5), 383-390. https://doi.org/10.1016/j.clbc.2020.12.011
Mahtani, Reshma, et al. "Advances in Therapeutic Approaches for Triple-Negative Breast Cancer." Clinical breast cancer vol. 21,5 (2021): 383-390. doi: https://doi.org/10.1016/j.clbc.2020.12.011
Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29. PMID: 33781662.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 86 entries